CARBIDOPA AND LEVODOPA (carbidopa and levodopa) by Dr. Reddy's Laboratories is dopa decarboxylase inhibitors [moa]. Approved for the treatment of parkinson's disease, post-encephalitic parkinsonism, symptomatic parkinsonism and 5 more indications. First approved in 1992.
Drug data last refreshed 20h ago
DOPA Decarboxylase Inhibitors
Aromatic Amino Acid
Worked on CARBIDOPA AND LEVODOPA at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo